leishmaniasis/oksendamine

Link salvestatakse lõikelauale

Artiklid Kliinilistes uuringutesPatendid

Valige sortimise tüüp

Leht 1 alates 74 tulemused

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Miltefosine has previously been shown to cure 97% of cases of visceral leishmaniasis (VL) in Indian adults. Because approximately one-half of cases of VL occur in children, we evaluated use of the adult dosage of miltefosin (2.5 mg/kg per day for 28 days) in 80 Indian children (age, 2-11 years) with

Fatal acute pancreatitis in a patient with visceral leishmaniasis during miltefosine treatment.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Pancreatitis is a known side effect of the once commonly used drug, sodium stibogluconate, for treatment of visceral leishmaniasis (VL). In India, miltefosine has recently been introduced as the first-line drug. Its side effects include loose motions, vomiting, and teratogenicity. We report here a

Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

We evaluated generic sodium stibogluconate (SSG) (International Dispensary Association, Amsterdam) versus Pentostam (sodium stibogluconate, GlaxoWellcome, London) under field conditions in Ethiopian patients with visceral leishmaniasis (VL; kala-azar). The 199 patients were randomly assigned to

Risk factors for in-hospital mortality from visceral leishmaniasis: A case-control study.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

The timely identification of visceral leishmaniasis (VL) patients with a higher risk of death is essential for meeting the target of reducing case-fatality rates in the Americas. This study aimed to identify factors associated with death from VL in the State of Piaui,

Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Meglumine antimoniate compounds have been the mainstay of treatment for cutaneous leishmaniasis (CL) for decades. We propose to evaluate the place of these drugs in this indication in Tunisia. We retrospectively reviewed medical records of 67 patients treated for (CL) using meglumine antimoniate at

Visceral Leishmaniasis with an Unusual Presentation in an HIV Positive Patient.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Visceral leishmaniasis is a disease caused by a haemoflagellate protozoan of the genus Leishmania. It has a wide geographical spread. Classic cases are found primarily in children and present with typical features that include fever, anaemia, hepatosplenomegaly, hypergammaglobulinaemia, and

Visceral leishmaniasis in children: a cohort of 120 patients in a metropolitan city of Brazil.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

There are few studies regarding the clinical presentation of visceral leishmaniasis (VL) in children. The aim of this study was to investigate the clinical manifestations, major complications and causes of death in children with VL. A retrospective study was performed with pediatric patients (< or =

Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Miltefosine (target dose of 2.5 mg/kg/day for 28 days) is the recommended treatment for visceral leishmaniasis (kala-azar) in Bangladesh on the basis of data from India. We evaluated miltefosine in a phase IV trial of 977 patients in Bangladesh. At the six-month final follow up, 701 were cured. 24

Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

OBJECTIVE 1) To determine the proportions of patients with visceral leishmaniasis who had various treatment outcomes when cared for under wartime conditions and with limited resources and 2) to identify patient characteristics associated with the outcomes. METHODS Cohort study. METHODS Médecins sans

Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Based on studies in India (as there was no studies from outside India) amphotericin B deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different

Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Leishmaniasis is a protozoan infection native to various countries, including those in South America and Southeast Asia. Although the incidence of leishmaniasis is low in the United States, it is an important cause of infection in individuals traveling to endemic areas. Various treatment modalities

Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Thirty-four multidrug-resistant cases of Indian visceral leishmaniasis (kala-azar) were treated with amphotericin B. A complete hemogram, liver and renal function tests, determination of serum electrolyte levels, a chest radiograph, and an electrocardiogram were done before, during, and after

Circulating and bone marrow myeloid cells containing Leishmania amastigotes in a case of advanced canine leishmaniosis.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

A 5-y-old male Poodle mix was presented with intermittent vomiting, anorexia, and weight loss. Physical examination revealed emaciation, lethargy, dehydration, hypothermia, respiratory distress, and splenomegaly. Based on clinicopathologic, serologic, and parasitologic findings, diagnoses of severe

Leishmaniosis in a dog with no travel history outside of the UK.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

A 3-year-old male neutered Shih Tzu cross was presented for investigation of a three-week history of weight loss, seborrhoea, vomiting and diarrhoea. Initial clinicopathological findings included pancytopenia, mild hypercalcaemia and marked hyperglobulinaemia. Subsequent bone marrow and skin

Visceral leishmaniasis and disseminated intravascular coagulation in a dog.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

A dog being treated with meglumine antimonate for leishmaniasis was examined because of anorexia, vomiting, diarrhea, weakness, and signs of abdominal discomfort. The history, physical examination findings, clinicopathologic abnormalities, and results of coagulation testing were compatible with a

Eelmine
1
2
3
4
5
Järgmine

Liitu meie
facebooki lehega

Herbal & Natural Medicine

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

Töötab 55 keeles
Taimsed ravimid, mida toetab teadus
Maitsetaimede äratundmine pildi järgi
Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
Lugege oma otsinguga seotud teaduspublikatsioone
Otsige ravimtaimi nende mõju järgi
Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel